Nevertheless, the fact that rSirt1 treatment prevented deleterious changes in transcriptional pathways involved in metabolic dysregulation, as well as in ageing and cancer-related pro-inflammatory pathways, supports the notion that targeting Sirt1 may help prevent a variety of comorbidities at the crossroads of metabolism, ageing and inflammation. The gene discussed is SIRT1; the disease is cancer.